Skip to main content

Table 1 Demographics of respondents in each country (N = 15 per country)

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

 

France

Germany

Italy

Spain

UK

Total

 

N = 15

N = 15

N = 15

N = 15

N = 15

N = 75

Speciality, n (%)

 Oncologist

5 (33)

1 (7)

3 (20)

0 (0)

0 (0)

9 (12)

 Haematologist

5 (33)

2 (13)

7 (47)

8 (53)

8 (53)

30 (40)

 Haemato-oncologist

5 (33)

12 (80)

5 (33)

7 (47)

7 (47)

36 (48)

Location, n (%)

 University hospital

7 (47)

10 (67)

7 (47)

13 (86)

11 (73)

48 (64)

 Cancer hospital/specialist centre

6 (40)

4 (27)

5 (33)

0 (0)

2 (13)

17 (23)

 Community/urban/general hospital

2 (13)

1 (7)

3 (20)

2 (13)

2 (13)

10 (13)

Experience, years

 Years treating adults with ALL, median (range)

15 (7–29)

12 (8–18)

10 (6–30)

16 (9–34)

12 (17–20)

N/A

Caseloada of ALL subtypes from 12 months before the survey, n

 ALL, median (range)

30 (3–200)

20 (6–100)

30 (5–100)

20 (3–230)

24 (4–200)

N/A

 R/R Ph(–) B-precursor ALL, median (range)

8 (1–75)

3 (1–21)

5 (1–50)

4 (0–55)

4 (1–50)

N/A

  1. aNumber of patients
  2. ALL acute lymphoblastic leukaemia, N/A not available, Ph(–) Philadelphia negative, R/R relapsed or refractory